Source::Xinhuanet
XINHUA/RSS
India's federal government has finalised arrangements with Hyderabad-based vaccine manufacturer, Biological-E, to reserve 300 million COVID-19 vaccine doses, officials said Thursday.
"Union (federal) ministry of health has finalised arrangements with Hyderabad based vaccine manufacturer Biological-E to reserve 30 crore (300 million) of COVID-19 vaccine doses. These vaccine doses will be manufactured and stockpiled by M/s Biological-E from August-December 2021. For this purpose, the union ministry of health would be making an advance payment of INR1500 crore (over 205 million U.S. dollars) to M/s Biological-E," an official statement said.
The vaccine being developed by Biological-E is a RBD protein sub-unit vaccine and is likely to be available in the next few months. The COVID-19 vaccine of Biological-E is currently undergoing Phase-3 clinical trial after showing promising results in Phase 1 and 2 clinical trials.
"The proposal of M/s Biological-E was examined and recommended for approval after due diligence by National Expert Group on Vaccine Administration for COVID-19 (NEGVAC)," the ministry said.
ALSO READ
